Effect of BDNF val66met polymorphism on declarative memory and its neural substrate: A meta-analysis

2012 ◽  
Vol 36 (9) ◽  
pp. 2165-2177 ◽  
Author(s):  
Joseph P. Kambeitz ◽  
Sagnik Bhattacharyya ◽  
Lana M. Kambeitz-Ilankovic ◽  
Isabel Valli ◽  
David A. Collier ◽  
...  
Keyword(s):  
Declarative Memory ◽  
Meta Analysis ◽  
Val66met Polymorphism ◽  
Neural Substrate ◽  
Bdnf Val66met Polymorphism

scholarly journals Association Between Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Methamphetamine Use Disorder: A Meta-Analysis

2020 ◽  
Vol 11 ◽  
Author(s):  
Li He ◽  
Yanhui Liao ◽  
Qiuxia Wu ◽  
Tieqiao Liu
Keyword(s):  
Neurotrophic Factor ◽  
Meta Analysis ◽  
Brain Derived Neurotrophic Factor ◽  
Current Data ◽  
Cochrane Library ◽  
Case Control Studies ◽  
Val66met Polymorphism ◽  
Asian Populations ◽  
Bdnf Val66met Polymorphism ◽  
Relationship Of

Background: Several studies had examined the association between brain-derived neurotrophic factor (BDNF) Val66Met polymorphism and methamphetamine (METH) use disorder, whereas the results were conflicting. The aim of this study was to conduct a meta-analysis to achieve a pooled effect size of the association between BDNF Val66Met polymorphism and METH use disorder.Methods: Literature searches were conducted in PubMed, EMBASE, and Cochrane Library up to July, 2020. All relevant studies on the relationship of BDNF Val66Met polymorphism and METH addiction were retrieved. Pooled odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated in the dominant, recessive, co-dominant, and allele model to appraise the association.Results: Seven case–control studies with a total of 2,204 subjects (956 METH-dependent cases and 1,248 healthy controls) were included in this meta-analysis. The results showed a significant correlation between BDNF Val66Met polymorphism and METH dependence in overall population under different genetic models. However, subgroup analysis indicated that the association only existed in Han Chinese but not in other Asian populations.Conclusion: Although the current data indicate that BDNF Val66Met polymorphism might be a potential genetic factor for METH use disorder, more researches are needed to prove its role in different populations.

scholarly journals BDNF Val66Met polymorphism and antipsychotic-induced tardive dyskinesia occurrence and severity: A meta-analysis

2014 ◽  
Vol 152 (2-3) ◽  
pp. 365-372 ◽  
Author(s):  
Itaru Miura ◽  
Jian-Ping Zhang ◽  
Masahiro Nitta ◽  
Todd Lencz ◽  
John M. Kane ◽  
...  
Keyword(s):  
Tardive Dyskinesia ◽  
Meta Analysis ◽  
Val66met Polymorphism ◽  
Bdnf Val66met Polymorphism

scholarly journals Replication and Meta-analysis of the Association between BDNF Val66Met Polymorphism and Cognitive Impairment in Patients Receiving Chemotherapy

2018 ◽  
Vol 56 (7) ◽  
pp. 4741-4750 ◽  
Author(s):  
Chia Jie Tan ◽  
Sheree Wan Ting Lim ◽  
Yi Long Toh ◽  
Terence Ng ◽  
Angie Yeo ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Meta Analysis ◽  
Val66met Polymorphism ◽  
Bdnf Val66met Polymorphism

scholarly journals Interaction between stress and the BDNF Val66Met polymorphism in depression: A systematic review and meta-analysis

2014 ◽  
Vol 55 (8) ◽  
pp. e52 ◽  
Author(s):  
Georgina M. Hosang ◽  
Celia Shiles ◽  
Katherine E. Tansey ◽  
Peter McGuffin ◽  
Rudolf Uher
Keyword(s):  
Systematic Review ◽  
Meta Analysis ◽  
Val66met Polymorphism ◽  
Bdnf Val66met Polymorphism

scholarly journals Brain derived neurotrophic factor (BDNF) Val66Met polymorphism is not risk factor for bipolar disorder

2019 ◽  
Author(s):  
Vandana Rai ◽  
Farhin Jamal ◽  
Pradeep Kumar
Keyword(s):  
Bipolar Disorder ◽  
Risk Factor ◽  
Meta Analysis ◽  
Pooled Analysis ◽  
Caucasian Population ◽  
Psychiatric Disease ◽  
Bdnf Gene ◽  
Genetic Studies ◽  
Val66met Polymorphism ◽  
Bdnf Val66met Polymorphism

AbstractBipolar disorder (BPD) is a psychiatric disease, characterized by the cycles of mania and depression. Several genetic studies investigated BDNF gene Val66Met polymorphism as risk factor for BPD, but results were inconclusive. Therefore, present meta-analysis was performed to reevaluate the BDNF Val66Met polymorphism and BPD association. Four databases (Pubmed, Springer Link, Science Direct and Google Scholar) were searched for eligible studies up to March 31,2018. Pooled odds ratios (OR) with 95% confidence intervals (CI) were calculated to estimate the strength of the association. All statistical analyses were done by MetaAnalyst and Mix program. Forty studies with a total of 28,787 subjects (10,085 cases and 18,702 controls) were included in this meta-analysis. Overall, pooled analysis indicated that there was no significant association between BDNF Val66Met polymorphism and BPD risk under all five genetic models (ORA vs.G =0.99, 95%CI= 0.94-1.03, p=0.49; ORAG vs. GG= 0.1.02, 95%CI= 0.95-1.07, p= 0.57; ORAA vs. GG = 0.98, 95%CI=0.89-1.08, p=0.75; ORAA+AG vs. GG= 1.0, 95%CI= 0.94-1.06, p= 0.89;ORAA vs. AG+GG= 0.96, 95%CI= 0.89-1.05, p= 0.47). Similarly, no significant association was observed in ethnicity based subgroup analysis in both Asian and Caucasian population. However, significant association was found in subtype analysis between BDNF Val66Met and BPDII (ORAA+AG vs. GG= 1.21, 95%CI= 1.06-1.37, p= 0.003) but not with BPDI. These findings suggested that the BDNF Val66Met polymorphism confer no genetic susceptibility to BPD I but risk for BPDII.

Sign in / Sign up

Export Citation Format

Share Document